{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T09:36:38Z","timestamp":1767951398294,"version":"3.49.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejso.2025.111178","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T01:35:39Z","timestamp":1762565739000},"page":"111178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined treatments based on interventional therapy improve the prognosis of patients with HCC: an umbrella review of systematic reviews and meta-analyses"],"prefix":"10.1016","volume":"52","author":[{"given":"Xianzhuo","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3957-6098","authenticated-orcid":false,"given":"Luyu","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengji","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","article-title":"Hepatocellular carcinoma: signaling pathways and therapeutic advances","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"issue":"9","key":"10.1016\/j.ejso.2025.111178_bib2","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int : Offic J Int Assoc Study Liver"},{"issue":"3","key":"10.1016\/j.ejso.2025.111178_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ejso.2025.111178_bib4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","article-title":"Management of hepatocellular carcinoma: a review","volume":"158","author":"Brown","year":"2023","journal-title":"JAMA Surg"},{"issue":"9","key":"10.1016\/j.ejso.2025.111178_bib5","doi-asserted-by":"crossref","first-page":"15230","DOI":"10.18632\/oncotarget.14774","article-title":"Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells","volume":"8","author":"Wei","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ejso.2025.111178_bib6","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.cgh.2023.01.039","article-title":"Breakthroughs in hepatocellular carcinoma therapies","volume":"21","author":"Singal","year":"2023","journal-title":"Clin Gastroenterol Hepatol : Offic Clinic Pract J Am Gastroenterolog Assoc"},{"issue":"4","key":"10.1016\/j.ejso.2025.111178_bib7","first-page":"1355","article-title":"Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: a meta-analysis","volume":"26","author":"Li","year":"2021","journal-title":"J BUON"},{"issue":"2","key":"10.1016\/j.ejso.2025.111178_bib8","first-page":"687","article-title":"Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"28","author":"Xian","year":"2024","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ejso.2025.111178_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1139025","article-title":"Transarterial chemoembolization with or without multikinase inhibitors for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Dong","year":"2023","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2025.111178_bib10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1159\/000536006","article-title":"Transarterial chemoembolization combined with lenvatinib for hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials","volume":"102","author":"Pei","year":"2024","journal-title":"Oncology"},{"issue":"8","key":"10.1016\/j.ejso.2025.111178_bib11","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2020.02.125","article-title":"A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis","volume":"8","author":"Zhao","year":"2020","journal-title":"Ann Transl Med"},{"issue":"6","key":"10.1016\/j.ejso.2025.111178_bib12","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/13645706.2022.2033786","article-title":"I-125 seeds insertion with TACE for advanced HCC: a meta-analysis of randomized controlled trials","volume":"31","author":"Hou","year":"2022","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"10.1016\/j.ejso.2025.111178_bib13","article-title":"Transcatheter arterial chemoembolization in combination with high-intensity focused ultrasound for intermediate and advanced hepatocellular carcinoma: a meta-analysis","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2025.111178_bib14","first-page":"10388","article-title":"Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials","volume":"8","author":"Fu","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"3","key":"10.1016\/j.ejso.2025.111178_bib15","article-title":"External beam radiotherapy for unresectable hepatocellular carcinoma","author":"Abdel-Rahman","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.ejso.2025.111178_bib16","first-page":"2043","article-title":"Thalidomide combined with transcatheter arterial chemoembolization (TACE) for intermediate or advanced hepatocellular carcinoma: a systematic review and GRADE approach","volume":"19","author":"Yang","year":"2018","journal-title":"Asian Pac J Cancer Prev APJCP : Asian Pac J Cancer Prev APJCP"},{"issue":"5","key":"10.1016\/j.ejso.2025.111178_bib17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0254-6272(17)30310-2","article-title":"Effect of Aidi injection plus transarterial chemoembolization on primary hepatic carcinoma: a systematic review and meta-analysis","volume":"37","author":"Shen","year":"2017","journal-title":"J Tradit Chin Med"},{"issue":"MAR","key":"10.1016\/j.ejso.2025.111178_bib18","article-title":"The therapeutic efficacy and safety of compound Kushen injection combined with transarterial chemoembolization in unresectable hepatocellular carcinoma: an update systematic review and meta-analysis","volume":"7","author":"Ma","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejso.2025.111178_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/15347354241293790","article-title":"Evaluation of the efficacy, safety, and clinical outcomes of ginsenosides as adjuvant therapy in hepatocellular carcinoma: a meta-analysis and systematic review","volume":"23","author":"Zhang","year":"2024","journal-title":"Integr Cancer Ther"},{"issue":"5","key":"10.1016\/j.ejso.2025.111178_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100729","article-title":"Combination of radiofrequency ablation and percutaneous ethanol injection versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"27","author":"Lu","year":"2022","journal-title":"Ann Hepatol"},{"issue":"7","key":"10.1016\/j.ejso.2025.111178_bib21","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00432-014-1677-4","article-title":"Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses","volume":"140","author":"Cheng","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2025.111178_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2478\/acph-2024-0019","article-title":"Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: a meta-analysis","volume":"74","author":"Xu","year":"2024","journal-title":"Acta Pharm"},{"issue":"18","key":"10.1016\/j.ejso.2025.111178_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010613","article-title":"Arsenic trioxide combined with transarterial chemoembolization for unresectable primary hepatic carcinoma: a systematic review and meta-analysis","volume":"97","author":"Song","year":"2018","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-017-1196-2","article-title":"Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis","volume":"15","author":"Luo","year":"2017","journal-title":"World J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-024-03282-z","article-title":"Embolization alone is as effective as TACE for unresectable HCC: systematic review and meta-analysis of randomized controlled trails","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"10.1016\/j.ejso.2025.111178_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e18591","article-title":"Traditional Chinese medicine combined with radiofrequency ablation improves primary liver cancer outcomes: a systematic review with meta-analysis","volume":"9","author":"Kong","year":"2023","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.ejso.2025.111178_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247958","article-title":"Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: a systematic review and meta-analysis","volume":"16","author":"Lemieux","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejso.2025.111178_bib28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3892\/ol.2024.14534","article-title":"Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"28","author":"Yu","year":"2024","journal-title":"Oncol Lett"},{"issue":"pagination","key":"10.1016\/j.ejso.2025.111178_bib29","article-title":"Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: a meta-analysis","volume":"257","author":"Wang","year":"2024","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.15403\/jgld-5159","article-title":"Comparing safety and efficacy of TACE plus apatinib in combination with a PD-1 inhibitor versus a non-triple therapy for treating advanced primary hepatocellular carcinoma: a systematic review and meta-analysis","volume":"33","author":"Pan","year":"2024","journal-title":"J Gastrointest Liver Diseas"},{"key":"10.1016\/j.ejso.2025.111178_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1421520","article-title":"Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis","volume":"15","author":"Fang","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib32","article-title":"Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis","volume":"15","author":"Du","year":"2024","journal-title":"Discov Oncol"},{"key":"10.1016\/j.ejso.2025.111178_bib33","article-title":"Efficacy and safety of PD-1 inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial chemo(embolization) for unresectable hepatocellular carcinoma: a meta-analysis","volume":"14","author":"Chen","year":"2024","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2025.111178_bib34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.hpb.2024.02.003","article-title":"Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"26","author":"Dawood","year":"2024","journal-title":"Hpb"},{"issue":"4","key":"10.1016\/j.ejso.2025.111178_bib35","first-page":"599","article-title":"The efficacy and safety of dendritic cells Co-Cultured with cytokine-induced killer cell therapy in combination with TACE-predominant minimally-invasive treatment for hepatocellular carcinoma: a meta-analysis","volume":"62","author":"Su","year":"2016","journal-title":"Clin Lab"},{"issue":"5","key":"10.1016\/j.ejso.2025.111178_bib36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.clinre.2014.04.010","article-title":"A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma","volume":"38","author":"Li","year":"2014","journal-title":"Clinic Res Hepatol Gastroenterol"},{"issue":"3","key":"10.1016\/j.ejso.2025.111178_bib37","doi-asserted-by":"crossref","DOI":"10.5306\/wjco.v15.i3.447","article-title":"Transarterial chemoembolization plus stent placement for hepatocellular carcinoma with main portal vein tumor thrombosis: a meta-analysis","volume":"15","author":"Sui","year":"2024","journal-title":"World J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2025.111178_bib38","article-title":"Transcatheter arterial chemoembolization combined with hepatic arterial infusion chemotherapy versus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"35","author":"Feng","year":"2024","journal-title":"Turk J Gastroenterol"},{"issue":"6","key":"10.1016\/j.ejso.2025.111178_bib39","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.4251\/wjgo.v16.i6.2793","article-title":"Meta-analysis of transarterial chemoembolization combined with cryoablation vs transarterial chemoembolization alone for \u2265 5 Cm hepatocellular carcinoma","volume":"16","author":"Cheng","year":"2024","journal-title":"World J Gastrointest Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2025.111178_bib40","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s12029-023-00940-5","article-title":"Stereotactic body radiation therapy with or without transarterial chemoembolization versus transarterial chemoembolization alone in early-stage hepatocellular carcinoma: a systematic review and meta-analysis","volume":"54","author":"Dumago","year":"2023","journal-title":"J Gastrointest Cancer"},{"issue":"5 May","key":"10.1016\/j.ejso.2025.111178_bib41","article-title":"Stereotactic body radiotherapy plus transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma patients with portal vein tumour thrombus: a meta-analysis","volume":"17","author":"Zhang","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib42","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/02656736.2022.2048095","article-title":"Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis","volume":"39","author":"Yang","year":"2022","journal-title":"Int J Hyperther"},{"issue":"6","key":"10.1016\/j.ejso.2025.111178_bib43","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/13645706.2022.2045326","article-title":"TACE with portal vein radioactive seeds for HCC with portal vein tumor thrombus: a meta-analysis","volume":"31","author":"Yang","year":"2022","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"10.1016\/j.ejso.2025.111178_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.948355","article-title":"Transarterial chemoembolization combined with radiofrequency ablation versus hepatectomy for hepatocellular carcinoma: a meta-analysis","volume":"9","author":"Dan","year":"2022","journal-title":"Front Surg"},{"issue":"4","key":"10.1016\/j.ejso.2025.111178_bib45","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.canrad.2020.12.003","article-title":"I125 irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: a meta-analysis","volume":"25","author":"Li","year":"2021","journal-title":"Cancer Radiother"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib46","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-021-02188-4","article-title":"Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis","volume":"19","author":"Jiang","year":"2021","journal-title":"World J Surg Oncol"},{"issue":"5\u20136","key":"10.1016\/j.ejso.2025.111178_bib47","first-page":"248","article-title":"Stereotactic body radiotherapy combined with transcatheter arterial chemoembolization versus stereotactic body radiotherapy alone as the first-line treatment for unresectable hepatocellular carcinoma: a meta-analysis and systematic review","volume":"64","author":"Zhao","year":"2020","journal-title":"Chemotherapy"},{"issue":"6","key":"10.1016\/j.ejso.2025.111178_bib48","doi-asserted-by":"crossref","first-page":"575","DOI":"10.5152\/dir.2020.19615","article-title":"Tace combined with microwave ablation therapy vs. tace alone for treatment of early-and intermediate-stage hepatocellular carcinomas larger than 5 cm: a meta-analysis","volume":"26","author":"Liu","year":"2020","journal-title":"Diagn Interv Radiol"},{"issue":"4","key":"10.1016\/j.ejso.2025.111178_bib49","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.brachy.2019.01.014","article-title":"(125)I seed implantation for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis","volume":"18","author":"Yuan","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ejso.2025.111178_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/TCRM.S126181","article-title":"Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a meta-analysis","volume":"13","author":"Zhao","year":"2017","journal-title":"Therapeut Clin Risk Manag"},{"key":"10.1016\/j.ejso.2025.111178_bib51","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.intimp.2016.09.015","article-title":"TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: a meta-analysis","volume":"40","author":"He","year":"2016","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.ejso.2025.111178_bib52","first-page":"803","article-title":"Efficacy and adverse reactions of transcatheter arterial chemoembolization combined with apatinib in the treatment of HCC with PVTT: a meta-analysis","volume":"29","author":"Xu","year":"2023","journal-title":"Alternat Therap Health Med"},{"issue":"2","key":"10.1016\/j.ejso.2025.111178_bib53","doi-asserted-by":"crossref","first-page":"222","DOI":"10.15403\/jgld-4729","article-title":"Safety and efficacy of TACE plus lenvatinib in treating advanced hepatocellular carcinoma: a systematic review and Meta- analysis","volume":"32","author":"Pan","year":"2023","journal-title":"J Gastrointest Liver Diseas"},{"issue":"35","key":"10.1016\/j.ejso.2025.111178_bib54","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034811","article-title":"Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: a meta-analysis","volume":"102","author":"Li","year":"2023","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib55","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-023-02961-7","article-title":"Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"21","author":"Duan","year":"2023","journal-title":"World J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2025.111178_bib56","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/2156587217730461","article-title":"Systematic review and meta-analysis of endostar combined with transcatheter arterial chemoembolization (TACE) versus TACE alone for hepatocellular carcinoma","volume":"22","author":"Zhang","year":"2017","journal-title":"J Evidence-based Complement Alternat Med"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12094-023-03232-3","article-title":"Transarterial embolization followed by staged hepatectomy versus emergency hepatectomy for ruptured HCC: a meta-analysis","volume":"26","author":"Pan","year":"2024","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2025.111178_bib58","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/00365521.2022.2057198","article-title":"Efficacy and safety of preoperative transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"57","author":"Mi","year":"2022","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib59","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-021-01790-6","article-title":"The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis","volume":"21","author":"Yang","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib60","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/13880209.2020.1799040","article-title":"Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese population","volume":"58","author":"Jia","year":"2020","journal-title":"Pharm Biol"},{"issue":"44","key":"10.1016\/j.ejso.2025.111178_bib61","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017813","article-title":"Elemene injection combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis","volume":"98","author":"Yao","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.ejso.2025.111178_bib62","doi-asserted-by":"crossref","first-page":"8835","DOI":"10.2147\/OTT.S182840","article-title":"Transcatheter hepatic arterial chemoembolization plus cinobufotalin injection adjuvant therapy for advanced hepatocellular carcinoma: a meta-analysis of 27 trials involving 2,079 patients","volume":"11","author":"Guo","year":"2018","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.ejso.2025.111178_bib63","article-title":"Treatment response, survival, and safety of transarterial chemoembolization with CalliSpheres microspheres versus conventional transarterial chemoembolization in hepatocellular carcinoma: a meta-analysis","volume":"11","author":"Liang","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2025.111178_bib64","first-page":"149","article-title":"Safety and efficacy of physical thermal ablation combined sorafenib for hepatocellular carcinoma: a meta-analysis","volume":"9","author":"Jin","year":"2021","journal-title":"J Clinic Translation Hepatol"},{"issue":"3","key":"10.1016\/j.ejso.2025.111178_bib65","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.12.004","article-title":"Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis","volume":"52","author":"Germani","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejso.2025.111178_bib66","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijsu.2018.03.049","article-title":"TransArterial ChemoEmbolization (TACE) with platinum versus anthracyclines for hepatocellular carcinoma: a meta-analysis","volume":"53","author":"Zhao","year":"2018","journal-title":"Int J Surg"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib67","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4254\/wjh.v16.i1.91","article-title":"Sorafenib plus transarterial chemoembolization vs sorafenib alone for patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"16","author":"Yang","year":"2024","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ejso.2025.111178_bib68","doi-asserted-by":"crossref","DOI":"10.25259\/JCIS_32_2024","article-title":"The efficacy of cone-beam computed tomography-guided transcatheter arterial chemoembolization in hepatocellular carcinoma survival: a systematic review","volume":"14","author":"Solim","year":"2024","journal-title":"J Clin Imaging Sci"},{"key":"10.1016\/j.ejso.2025.111178_bib69","first-page":"1","article-title":"Meta-analysis on the therapeutic effect of transcatheter arterial chemoembolization combined with portal vein embolization","author":"Liu","year":"2024","journal-title":"Chemotherapy"},{"issue":"3","key":"10.1016\/j.ejso.2025.111178_bib70","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000036865","article-title":"The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"103","author":"Li","year":"2024","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.ejso.2025.111178_bib71","article-title":"Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): a systematic review and meta-analysis","volume":"48","author":"Ji","year":"2024","journal-title":"Clinic Res Hepatol Gastroenterol"},{"issue":"18","key":"10.1016\/j.ejso.2025.111178_bib72","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038037","article-title":"Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"103","author":"Feng","year":"2024","journal-title":"Medicine"},{"issue":"26","key":"10.1016\/j.ejso.2025.111178_bib73","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034165","article-title":"Effect of Chinese medicines combined with transarterial chemoembolization on primary hepatic carcinoma: a systematic review and meta-analysis","volume":"102","author":"Xu","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.ejso.2025.111178_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1106827","article-title":"Adjuvant effect of herbal medicine on transarterial chemoembolization in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"13","author":"Oh","year":"2023","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2025.111178_bib75","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s13304-023-01596-3","article-title":"Sequential transcatheter arterial chemoembolization and portal vein embolization before hepatectomy for the management of patients with hepatocellular carcinoma: a systematic review and meta-analysis (Jul, 10.1007\/s13304-023-01571-y, 2023)","volume":"75","author":"Liao","year":"2023","journal-title":"Update Surg"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib76","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/curroncol30010096","article-title":"Efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors for hepatocellular carcinoma patients with portal vein tumor thrombus: a systematic review and meta-analysis","volume":"30","author":"Deng","year":"2023","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2025.111178_bib77","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/00015458.2023.2256539","article-title":"Preoperative transarterial chemoembolization (TACE) plus liver resection versus upfront liver resection for large hepatocellular carcinoma (=5?cm): a systematic review and meta-analysis","volume":"123","author":"Chan","year":"2023","journal-title":"Acta Chir Belg"},{"issue":"3","key":"10.1016\/j.ejso.2025.111178_bib78","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00261-021-03368-2","article-title":"Comparison of combined transarterial chemoembolization and ablations in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"47","author":"Keshavarz","year":"2022","journal-title":"Abdomin Radiol"},{"issue":"23","key":"10.1016\/j.ejso.2025.111178_bib79","doi-asserted-by":"crossref","first-page":"8432","DOI":"10.1002\/cam4.4350","article-title":"Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"10","author":"Li","year":"2021","journal-title":"Cancer Med"},{"issue":"24","key":"10.1016\/j.ejso.2025.111178_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246172","article-title":"Conventional transarterial chemoembolization versus drug-eluting beads in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"13","author":"Bzeizi","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib81","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1080\/02656736.2020.1774667","article-title":"Comparison of transcatheter arterial chemoembolization combined with radiofrequency ablation or microwave ablation for the treatment of unresectable hepatocellular carcinoma: a systemic review and meta-analysis","volume":"37","author":"Zhao","year":"2020","journal-title":"Int J Hyperther"},{"issue":"2","key":"10.1016\/j.ejso.2025.111178_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227475","article-title":"Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: a systematic review","volume":"15","author":"Yang","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ejso.2025.111178_bib83","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.hpb.2019.12.013","article-title":"A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma","volume":"22","author":"Ma","year":"2020","journal-title":"Hpb"},{"issue":"4","key":"10.1016\/j.ejso.2025.111178_bib84","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.clinre.2018.09.006","article-title":"A meta-analysis of the efficacy and safety of iodine 131I metuximab infusion combined with TACE for treatment of hepatocellular carcinoma","volume":"43","author":"Fan","year":"2019","journal-title":"Clinic Res Hepatol Gastroenterol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib85","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4103\/jcrt.JCRT_1261_16","article-title":"Efficacy and safety of epirubicin applied in transcatheter arterial chemoembolization for hepatocellular carcinoma: a meta-analysis","volume":"14","author":"Bai","year":"2018","journal-title":"J Cancer Res Therapeut"},{"issue":"3","key":"10.1016\/j.ejso.2025.111178_bib86","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5301\/tj.5000491","article-title":"Transarterial chemoembolization combination therapy vs monotherapy in unresectable hepatocellular carcinoma: a meta-analysis","volume":"102","author":"Li","year":"2016","journal-title":"Tumori J"},{"key":"10.1016\/j.ejso.2025.111178_bib87","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.12659\/MSM.895548","article-title":"Improvement of survival rate for patients with hepatocellular carcinoma using transarterial chemoembolization in combination with three-dimensional conformal radiation therapy: a meta-analysis","volume":"22","author":"Bai","year":"2016","journal-title":"Med Sci Monit"},{"issue":"17","key":"10.1016\/j.ejso.2025.111178_bib88","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.7314\/APJCP.2015.16.17.7871","article-title":"Hepatic resection after initial transarterial chemoembolization versus transarterial chemoembolization alone for the treatment of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"16","author":"Tang","year":"2015","journal-title":"Asian Pac J Cancer Prev APJCP : Asian Pac J Cancer Prev APJCP"},{"issue":"45","key":"10.1016\/j.ejso.2025.111178_bib89","doi-asserted-by":"crossref","first-page":"17206","DOI":"10.3748\/wjg.v20.i45.17206","article-title":"Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis","volume":"20","author":"Ni","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.ejso.2025.111178_bib90","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00432-013-1528-8","article-title":"Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis","volume":"140","author":"Gu","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2025.111178_bib91","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jso.25338","article-title":"Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and meta-analysis","volume":"119","author":"Moran","year":"2019","journal-title":"J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2025.111178_bib92","first-page":"974","article-title":"Hepatic resection combined with radiofrequency ablation versus hepatic resection alone for multifocal hepatocellular carcinomas: a meta-analysis","volume":"37","author":"Xu","year":"2017","journal-title":"J Huazhong Univer Sci Technol Med Sci = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban"},{"issue":"6","key":"10.1016\/j.ejso.2025.111178_bib93","first-page":"1525","article-title":"Sorafenib combined with radiofrequency ablation as treatment for patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"22","author":"Chen","year":"2017","journal-title":"J Buon"},{"key":"10.1016\/j.ejso.2025.111178_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122540","article-title":"Molecular mechanisms of TACE refractoriness: directions for improvement of the TACE procedure","volume":"342","author":"Li","year":"2024","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib95","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol : Offic J Am Soc Clinic Oncol"},{"issue":"16","key":"10.1016\/j.ejso.2025.111178_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17162642","article-title":"Angiogenetic factors in hepatocellular carcinoma during transarterial chemoembolization: a pilot study","volume":"17","author":"Osredkar","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejso.2025.111178_bib97","article-title":"Interactions between anti-angiogenic therapy and immunotherapy in glioblastoma","volume":"11","author":"Jain","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2025.111178_bib98","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cac2.12183","article-title":"Improving antitumor immunity using antiangiogenic agents: mechanistic insights, current progress, and clinical challenges","volume":"41","author":"Li","year":"2021","journal-title":"Cancer Commun"},{"issue":"24","key":"10.1016\/j.ejso.2025.111178_bib99","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejso.2025.111178_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.752725","article-title":"Improving outcomes of tyrosine kinase inhibitors in hepatocellular carcinoma: new data and ongoing trials","volume":"11","author":"Mou","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2025.111178_bib101","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jhep.2011.01.047","article-title":"Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma","volume":"55","author":"Tai","year":"2011","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib102","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib103","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12893-021-01307-y","article-title":"HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Surg"},{"key":"10.1016\/j.ejso.2025.111178_bib104","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4756147","article-title":"Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery","volume":"2018","author":"Shiina","year":"2018","journal-title":"Canadian J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ejso.2025.111178_bib105","first-page":"495","article-title":"Effect of the combination treatment of high-intensity focused ultrasound and cryocare knife in advanced liver cancer","volume":"22","author":"Zhai","year":"2017","journal-title":"J BUON : Offic J Balkan Union Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2025.111178_bib106","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ctrv.2006.08.002","article-title":"Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies","volume":"32","author":"Marelli","year":"2006","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.ejso.2025.111178_bib107","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010472","article-title":"Ethanol inhibits the growth and metastasis of hepatocellular carcinoma by inducing immunogenic cell death","volume":"13","author":"Hsu","year":"2025","journal-title":"J immunother Cancer"},{"issue":"9","key":"10.1016\/j.ejso.2025.111178_bib108","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.26992","article-title":"Long-term outcomes of transcatheter arterial chemoembolization combined with radiofrequency ablation as an initial treatment for early-stage hepatocellular carcinoma","volume":"4","author":"Zhang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ejso.2025.111178_bib109","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3348\/kjr.2018.19.2.237","article-title":"Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation versus transarterial chemoembolization alone in patients with a large solitary or multinodular hepatocellular carcinomas","volume":"19","author":"Zheng","year":"2018","journal-title":"Korean J Radiol"},{"issue":"3","key":"10.1016\/j.ejso.2025.111178_bib110","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3892\/ol.2020.11765","article-title":"Enhanced therapeutic effect of transcatheter arterial chemoembolization combined with radioactive I-125 seed implantation on liver cancer","volume":"20","author":"Liu","year":"2020","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib111","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12876-022-02356-0","article-title":"I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular hepatocellular carcinoma","volume":"22","author":"Gao","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"10.1016\/j.ejso.2025.111178_bib112","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ijrobp.2024.09.021","article-title":"External beam radiation therapy after transarterial chemoembolization versus transarterial chemoembolization alone for treatment of inoperable hepatocellular carcinoma: a randomized phase 3 trial","volume":"121","author":"Chen","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.ejso.2025.111178_bib113","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.7150\/jca.15405","article-title":"The degree of lipiodol accumulation can be an indicator of successful treatment for unresectable hepatocellular carcinoma (HCC) patients - in the case of transcatheter arterial chemoembolization (TACE) and external beam radiotherapy (EBRT)","volume":"7","author":"Yang","year":"2016","journal-title":"J Cancer"},{"issue":"5971","key":"10.1016\/j.ejso.2025.111178_bib114","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science (New York, NY)"},{"issue":"4","key":"10.1016\/j.ejso.2025.111178_bib115","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/j.seminoncol.2015.05.015","article-title":"Anticancer cytokines: biology and clinical effects of Interferon-\u03b12, interleukin (IL)-2, IL-15, IL-21, and IL-12","volume":"42","author":"Floros","year":"2015","journal-title":"Semin Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2025.111178_bib116","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0006-2952(99)00388-3","article-title":"Mechanism of action in thalidomide teratogenesis","volume":"59","author":"Stephens","year":"2000","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.ejso.2025.111178_bib117","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/(SICI)1096-9926(200003)61:3<189::AID-TERA6>3.0.CO;2-W","article-title":"Hypothesis: thalidomide embryopathy-proposed mechanism of action","volume":"61","author":"Stephens","year":"2000","journal-title":"Teratology"},{"issue":"2","key":"10.1016\/j.ejso.2025.111178_bib118","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/1751-2980.12114","article-title":"Thalidomide-induced angiopoietin 2, Notch1 and Dll4 downregulation under hypoxic condition in tissues with gastrointestinal vascular malformation and human umbilical vein endothelial cells","volume":"15","author":"Feng","year":"2014","journal-title":"J Dig Dis"},{"issue":"12","key":"10.1016\/j.ejso.2025.111178_bib119","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1007\/s10620-014-3257-5","article-title":"Inhibition of endothelial Slit2\/Robo1 signaling by thalidomide restrains angiogenesis by blocking the PI3K\/Akt pathway","volume":"59","author":"Li","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.ejso.2025.111178_bib120","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nm.2131","article-title":"Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia","volume":"16","author":"Lebrin","year":"2010","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ejso.2025.111178_bib121","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol Rev"},{"issue":"12","key":"10.1016\/j.ejso.2025.111178_bib122","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1634\/theoncologist.2014-0283","article-title":"Chronic thalidomide and chemoembolization for hepatocellular carcinoma","volume":"19","author":"Wu","year":"2014","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ejso.2025.111178_bib123","first-page":"480","article-title":"Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma","volume":"11","author":"Zhong","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ejso.2025.111178_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153700","article-title":"Efficacy and safety of transcatheter arterial chemoembolization combined with ginsenosides in hepatocellular carcinoma treatment","volume":"91","author":"Zhu","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejso.2025.111178_bib125","article-title":"Chinese medicines as an adjuvant therapy for unresectable hepatocellular carcinoma during transarterial chemoembolization: a meta-analysis of randomized controlled trials","volume":"2013","author":"Cheung","year":"2013","journal-title":"Evid base Compl Alternative Med eCAM"},{"issue":"5","key":"10.1016\/j.ejso.2025.111178_bib126","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Cancer Netw : J Natl Compr Cancer Netw"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib127","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/JS9.0000000000001889","article-title":"Optimal candidates and surrogate endpoints for HAIC versus Sorafenib in hepatocellular carcinoma: an updated systematic review and meta-analysis","volume":"111","author":"Si","year":"2025","journal-title":"Int J Surg"},{"issue":"15","key":"10.1016\/j.ejso.2025.111178_bib128","doi-asserted-by":"crossref","first-page":"14451","DOI":"10.1007\/s00432-023-05231-x","article-title":"Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"149","author":"Liu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejso.2025.111178_bib129","article-title":"Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ejso.2025.111178_bib130","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12072-023-10591-0","article-title":"TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis","volume":"18","author":"Liu","year":"2024","journal-title":"Hepatol Int"},{"issue":"10474","key":"10.1016\/j.ejso.2025.111178_bib131","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"10474","key":"10.1016\/j.ejso.2025.111178_bib132","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2025.111178_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102622","volume":"72","author":"Jin","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"12","key":"10.1016\/j.ejso.2025.111178_bib134","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1007\/s00330-023-09754-2","article-title":"Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study","volume":"33","author":"Jin","year":"2023","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111178_bib135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","article-title":"Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"3","key":"10.1016\/j.ejso.2025.111178_bib136","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/cam4.5125","article-title":"TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis","volume":"12","author":"Brown","year":"2023","journal-title":"Cancer Med"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325016063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325016063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:59:19Z","timestamp":1767945559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325016063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0748798325016063"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111178","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined treatments based on interventional therapy improve the prognosis of patients with HCC: an umbrella review of systematic reviews and meta-analyses","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111178"}}